vs

Side-by-side financial comparison of IRIDEX CORP (IRIX) and MIDDLEFIELD BANC CORP (MBCN). Click either name above to swap in a different company.

MIDDLEFIELD BANC CORP is the larger business by last-quarter revenue ($19.9M vs $14.7M, roughly 1.4× IRIDEX CORP). On growth, MIDDLEFIELD BANC CORP posted the faster year-over-year revenue change (18.3% vs -69.7%). Over the past eight quarters, MIDDLEFIELD BANC CORP's revenue compounded faster (13.7% CAGR vs 11.9%).

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

Star Banc Corporation was a Cincinnati, Ohio-based regional bank holding company that acquired Firstar in 1998 and took the Firstar name; the merged bank acquired U.S. Bancorp in 2001 and took the U.S. Bancorp name. The company can trace its origins back to 1863 when it was first founded as the First National Bank of Cincinnati.

IRIX vs MBCN — Head-to-Head

Bigger by revenue
MBCN
MBCN
1.4× larger
MBCN
$19.9M
$14.7M
IRIX
Growing faster (revenue YoY)
MBCN
MBCN
+88.0% gap
MBCN
18.3%
-69.7%
IRIX
Faster 2-yr revenue CAGR
MBCN
MBCN
Annualised
MBCN
13.7%
11.9%
IRIX

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
IRIX
IRIX
MBCN
MBCN
Revenue
$14.7M
$19.9M
Net Profit
$5.3M
Gross Margin
37.2%
Operating Margin
32.2%
Net Margin
26.7%
Revenue YoY
-69.7%
18.3%
Net Profit YoY
127.4%
EPS (diluted)
$0.65

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRIX
IRIX
MBCN
MBCN
Q4 25
$14.7M
Q3 25
$12.5M
$19.9M
Q2 25
$13.6M
$20.5M
Q1 25
$11.9M
$18.0M
Q4 24
$12.7M
$17.5M
Q3 24
$11.6M
$16.8M
Q2 24
$12.6M
$16.8M
Q1 24
$11.8M
$16.8M
Net Profit
IRIX
IRIX
MBCN
MBCN
Q4 25
Q3 25
$-1.6M
$5.3M
Q2 25
$-994.0K
$6.2M
Q1 25
$-1.7M
$4.8M
Q4 24
$-834.0K
$4.8M
Q3 24
$-1.9M
$2.3M
Q2 24
$-2.7M
$4.2M
Q1 24
$-3.5M
$4.2M
Gross Margin
IRIX
IRIX
MBCN
MBCN
Q4 25
37.2%
Q3 25
32.1%
Q2 25
34.5%
Q1 25
42.5%
Q4 24
44.0%
Q3 24
37.3%
Q2 24
40.7%
Q1 24
37.9%
Operating Margin
IRIX
IRIX
MBCN
MBCN
Q4 25
Q3 25
-11.3%
32.2%
Q2 25
-6.9%
35.9%
Q1 25
-1.7%
31.9%
Q4 24
-3.9%
33.4%
Q3 24
-16.1%
16.1%
Q2 24
-20.9%
28.8%
Q1 24
-28.0%
29.4%
Net Margin
IRIX
IRIX
MBCN
MBCN
Q4 25
Q3 25
-12.6%
26.7%
Q2 25
-7.3%
30.0%
Q1 25
-14.2%
26.8%
Q4 24
-6.6%
27.8%
Q3 24
-16.7%
13.9%
Q2 24
-21.2%
24.7%
Q1 24
-29.5%
24.9%
EPS (diluted)
IRIX
IRIX
MBCN
MBCN
Q4 25
Q3 25
$-0.09
$0.65
Q2 25
$-0.06
$0.76
Q1 25
$-0.10
$0.60
Q4 24
$-0.05
$0.60
Q3 24
$-0.12
$0.29
Q2 24
$-0.16
$0.52
Q1 24
$-0.21
$0.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRIX
IRIX
MBCN
MBCN
Cash + ST InvestmentsLiquidity on hand
$6.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$224.1M
Total Assets
$29.2M
$2.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRIX
IRIX
MBCN
MBCN
Q4 25
$6.0M
Q3 25
$5.6M
Q2 25
$6.8M
Q1 25
$7.2M
Q4 24
$2.4M
Q3 24
$3.9M
Q2 24
$4.1M
Q1 24
$5.4M
Total Debt
IRIX
IRIX
MBCN
MBCN
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$1.0M
Q3 24
$1.4M
Q2 24
Q1 24
Stockholders' Equity
IRIX
IRIX
MBCN
MBCN
Q4 25
Q3 25
$4.7M
$224.1M
Q2 25
$6.1M
$216.1M
Q1 25
$852.0K
$213.8M
Q4 24
$2.1M
$210.6M
Q3 24
$2.6M
$210.7M
Q2 24
$4.2M
$206.8M
Q1 24
$6.5M
$205.6M
Total Assets
IRIX
IRIX
MBCN
MBCN
Q4 25
$29.2M
Q3 25
$28.4M
$2.0B
Q2 25
$31.6M
$1.9B
Q1 25
$34.2M
$1.9B
Q4 24
$29.1M
$1.9B
Q3 24
$30.2M
$1.9B
Q2 24
$31.2M
$1.8B
Q1 24
$34.1M
$1.8B
Debt / Equity
IRIX
IRIX
MBCN
MBCN
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.48×
Q3 24
0.53×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRIX
IRIX
MBCN
MBCN
Operating Cash FlowLast quarter
$4.8M
Free Cash FlowOCF − Capex
$3.4M
FCF MarginFCF / Revenue
17.0%
Capex IntensityCapex / Revenue
7.2%
Cash ConversionOCF / Net Profit
0.91×
TTM Free Cash FlowTrailing 4 quarters
$32.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRIX
IRIX
MBCN
MBCN
Q4 25
Q3 25
$-1.2M
$4.8M
Q2 25
$-397.0K
$4.8M
Q1 25
$-1.1M
$8.0M
Q4 24
$-1.2M
$17.5M
Q3 24
$-3.1M
$6.0M
Q2 24
$-1.3M
$3.4M
Q1 24
$-1.6M
$5.4M
Free Cash Flow
IRIX
IRIX
MBCN
MBCN
Q4 25
Q3 25
$-1.2M
$3.4M
Q2 25
$-410.0K
$4.2M
Q1 25
$-1.2M
$7.7M
Q4 24
$-1.2M
$16.7M
Q3 24
$-3.1M
$5.8M
Q2 24
$3.3M
Q1 24
$-1.7M
$5.3M
FCF Margin
IRIX
IRIX
MBCN
MBCN
Q4 25
Q3 25
-9.4%
17.0%
Q2 25
-3.0%
20.5%
Q1 25
-9.8%
42.9%
Q4 24
-9.8%
95.6%
Q3 24
-26.5%
34.7%
Q2 24
19.3%
Q1 24
-14.0%
31.9%
Capex Intensity
IRIX
IRIX
MBCN
MBCN
Q4 25
Q3 25
0.1%
7.2%
Q2 25
0.1%
3.0%
Q1 25
0.1%
1.5%
Q4 24
0.1%
4.4%
Q3 24
0.0%
1.0%
Q2 24
0.0%
0.6%
Q1 24
0.0%
0.5%
Cash Conversion
IRIX
IRIX
MBCN
MBCN
Q4 25
Q3 25
0.91×
Q2 25
0.78×
Q1 25
1.66×
Q4 24
3.60×
Q3 24
2.57×
Q2 24
0.81×
Q1 24
1.31×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons